연구성과로 돌아가기

2024 연구성과 (139 / 286)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
WoS SCOPUS Document Type Document Title Abstract Authors Affiliation ResearcherID (WoS) AuthorsID (SCOPUS) Author Email(s) Journal Name JCR Abbreviation ISSN eISSN Volume Issue WoS Edition WoS Category JCR Year IF JCR (%) FWCI FWCI Update Date WoS Citation SCOPUS Citation Keywords (WoS) KeywordsPlus (WoS) Keywords (SCOPUS) KeywordsPlus (SCOPUS) Language Publication Stage Publication Year Publication Date DOI JCR Link DOI Link WOS Link SCOPUS Link
Review A review on tyrosine kinase inhibitors for targeted breast cancer therapy Breast cancer is a heterogeneous disease with complex molecular pathogenesis. Overexpression of several tyrosine kinase receptors is associated with poor prognosis, therefore, they can be key targets in breast cancer therapy. Tyrosine kinase inhibitors (TKIs) have emerged as leading agents in targeted cancer therapy due to their effectiveness in disrupting key molecular pathways involved in tumor growth. TKIs target various tyrosine kinases, including the human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), Vascular endothelial growth factor receptor (VEGFR), anaplastic lymphoma kinase (ALK), vascular endothelial growth factor receptor (VEGFR)-associated multi-targets, rearranged during transfection (RET), fibroblast growth factor receptor (FGFR), receptor tyrosine kinase-like orphan signal 1 (ROS1), Mitogenactivated protein kinase (MAPK), and tropomyosin receptor kinase (TRK). These drugs target the tyrosine kinase domain of receptor tyrosine kinases and play a vital role in proliferation and migration of breast cancer cells. Several TKIs, including lapatinib, neratinib, and tucatinib, have been developed and are currently used in clinical settings, often in combination with chemotherapy, endocrine therapy, or other targeted agents. TKIs have demonstrated remarkable benefits in enhancing progression-free and overall survival in patients with breast cancer and have become a standard of care for this population. This review provides an overview of TKIs currently being examined in preclinical studies and clinical trials, especially in combination with drugs approved for breast cancer treatment. TKIs have emerged as a promising therapeutic option for patients with breast cancer and hold potential for treating other breast cancer subtypes. The development of new TKIs and their integration into personalized treatment strategies will continue to shape the future of breast cancer therapy. Sankarapandian, Vidya; Rajendran, Ramya Lakshmi; Miruka, Conrad Ondieki; Sivamani, Poornima; Maran, Balu Alagar Venmathi; Krishnamoorthy, Rajapandiyan; Gangadaran, Prakash; Ahn, Byeong-Cheol Kampala Int Univ, Dept Microbiol & Immunol, Western Campus,Box 20000, Kampala, Uganda; Kyungpook Natl Univ, Sch Med, Dept Nucl Med, 680,Gukchaebosang Ro, Daegu 41944, South Korea; Kampala Int Univ, Dept Biochem, Western Campus,Box 20000, Kampala, Uganda; Christian Med Coll & Hosp, Dept Pharmacol & Clin pharmacol, Vellore 632004, India; Nagasaki Univ, Grad Sch Integrated Sci & Technol, 1-14 Bunkyomachi, Nagasaki 8528521, Japan; King Saud Univ, Coll Food & Agr Sci, Dept Food Sci & Nutr, Riyadh 11451, Saudi Arabia; Kyungpook Natl Univ, Sch Med, Dept Biomed Sci, FOUR KNU Convergence Educ Program Biomed Sci Creat, Daegu 41944, South Korea; Kyungpook Natl Univ Hosp, Dept Nucl Med, Daegu 41944, South Korea; Kyungpook Natl Univ, Cardiovasc Res Inst, Daegu 41944, South Korea Venmathi Maran, Balu Alagar/G-5163-2014; Rajendran, Ramya/AAV-6338-2021; Gangadaran, Prakash/AAV-3102-2021; Krishnamoorthy, Rajapandiyan/ABD-2564-2020; Miruka, Conrad/ACE-3698-2022 57395459900; 57195318729; 57443680700; 49061497000; 58789989400; 7102527961; 54393130400; 7202791511 prakashg@knu.ac.kr;abc2000@knu.ac.kr; PATHOLOGY RESEARCH AND PRACTICE PATHOL RES PRACT 0344-0338 1618-0631 263 SCIE PATHOLOGY 2024 3.2 25.0 0.25 2025-05-07 3 3 Tyrosine Kinase inhibitors; Breast cancer; Human epidermal growth factor; Chemotherapy GROWTH-FACTOR RECEPTOR; MEK INHIBITOR; IN-SITU; RET; LUNG; BIOLOGY; PROTEIN; RESISTANCE; ESTROGEN; CELLS Breast cancer; Chemotherapy; Human epidermal growth factor; Tyrosine Kinase inhibitors Antineoplastic Agents; Breast Neoplasms; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors; antineoplastic agent; protein kinase inhibitor; protein tyrosine kinase inhibitor; breast tumor; drug therapy; female; human; molecularly targeted therapy; pathology; procedures English 2024 2024-11 10.1016/j.prp.2024.155607 바로가기 바로가기 바로가기 바로가기
Article DRL-assisted task offloading in enhanced time-expanded graph (eTEG)-modeled aerial computing Space-air-ground integrated networks (SAGINs), categorized under aerial computing (AC), are emerging as a promising hierarchical platform designed to meet the seamless connectivity demands of the forthcoming 6G era. However, efficiently offloading ground tasks to space entities via SAGINs presents unprecedented challenges, primarily due to the mobility of these networks. In response, an enhanced time-expanded graph (eTEG) is proposed to model the dynamic distribution of heterogeneous SAGIN resources, including transmission bandwidth, computation, and storage, thereby optimizing task offloading and resource allocation by employing eTEG. Specifically, this optimization challenge is addressed using a deep reinforcement learning (DRL) approach, aimed at streamlining decision-making for task offloading and resource management to significantly reduce end-to-end delay and enhance network performance. Simulation experiments conducted to evaluate the proposed DRL-based method demonstrate its effectiveness in reducing energy consumption and improving stability, thereby outperforming other methods by achieving reduced delays and satisfying user requirements. Mo, Jiang; Zhao, Ke; Peng, Limei; Lee, Jiyeon; Ma, Li; Pu, Lixin; Fan, Jipeng Kyungpook Natl Univ, Sch Comp Sci & Engn, Deagu, South Korea; Hubei Univ Chinese Med, Coll Informat Engn, Wuhan 430065, Hubei, Peoples R China; UESTC, Shenzhen Inst Adv Study, Shenzhen, Peoples R China; Chengdu Chengdian Goldisc Hlth Data Technol Co Ltd, Chengdu 611731, Peoples R China zhao, ke/MGB-2778-2025 58068977900; 57439189700; 7201574271; 58377757200; 58452680000; 57722507700; 57217069140 mojiang@knu.ac.kr;kezhao@knu.ac.kr;auroraplm@knu.ac.kr;jiyeon@knu.ac.kr;mary0807@hbucm.edu.cn;plx@uestc.edu.cn;fanjipeng@gdpacs.com; COMPUTER COMMUNICATIONS COMPUT COMMUN 0140-3664 1873-703X 228 SCIE ENGINEERING, ELECTRICAL & ELECTRONIC;TELECOMMUNICATIONS;COMPUTER SCIENCE, INFORMATION SYSTEMS 2024 4.3 25.0 0.35 2025-05-07 0 1 Dynamic resource allocation; Space-air-ground networks; Data offloading; Deep reinforcement learning; Time-expanded graph RESOURCE-ALLOCATION; FLOWS Data offloading; Deep reinforcement learning; Dynamic resource allocation; Space–air–ground networks; Time-expanded graph Antenna grounds; Computation offloading; Reinforcement learning; Resource allocation; Air grounds; Data offloading; Dynamic resource allocations; Ground networks; Hierarchical platforms; Integrated networks; Reinforcement learnings; Space–air–ground network; Task offloading; Time-expanded graph; Deep reinforcement learning English 2024 2024-12-01 10.1016/j.comcom.2024.107954 바로가기 바로가기 바로가기 바로가기
Article Effect of probiotics and acidifiers on feed intake, egg mass, production performance, and egg yolk chemical composition in late-laying quails Background and Aim: Probiotics can be used as an alternative to antibiotic growth promoters because antibiotics are prohibited worldwide. This study investigated the potential combination of probiotics and acidifiers to improve feed intake, productive performance, egg mass, and egg yolk chemical composition of late -laying quail for the health of humans who consume quail products. Materials and Methods: One hundred laying quails were divided into 4 x 5 treatments, with each group consisting of five replications. The adaptation period was 2 weeks, and the treatment was continued for 4 weeks. Probiotics and acidifiers were added to drinking water and incorporated into the diet. Feed and water were provided ad libitum. Treatment duration (1 week, 2 weeks, 3 weeks, and 4 weeks) and additional feed treatment (control, probiotic 2% + 0.5% acidifier, probiotic 2% + 1% acidifier, probiotic 4% + 0.5% acidifier, and probiotic 4% + 1% acidifier, respectively). Results: Significant differences (p < 0.05) were observed in feed intake, quail day production, feed efficiency, egg mass in laying quails, and the chemical composition of egg yolk with probiotics and acidifiers in late -laying quails. Conclusion: The combination of probiotics and acidifiers can improve feed intake, production performance, egg mass, and egg yolk chemical composition in late -laying quails. Lokapirnasari, Widya Paramita; Al-Arif, Mohammad Anam; Hidayatik, Nanik; Safiranisa, Aldhia; Arumdani, Dynda Febriana; Zahirah, Amadea Inas; Yulianto, Andreas Berny; Lamid, Mirni; Marbun, Tabita Dameria; Lisnanti, Ertika Fitri; Baihaqi, Zein Ahmad; Khairullah, Aswin Rafif; Kurniawan, Shendy Canadya; Pelawi, Erlycasna Beru Sembiring; Hasib, Abdullah Univ Airlangga, Fac Vet Med, Div Anim Husb, Jl Mulyorejo, Surabaya 60115, East Java, Indonesia; Univ Airlangga, Fac Vet Med, Div Vet Basic Med, Jl Mulyorejo,Kampus C Mulyorejo, Surabaya 60115, East Java, Indonesia; Univ Airlangga, Fac Vet Med, Surabaya 60115, East Java, Indonesia; Univ Wijaya Kusuma Surabaya, Fac Vet Med, Jl Dukuh Kupang 25 54, Surabaya 60225, East Java, Indonesia; Kyungpook Natl Univ, Anim Nutr Lab, Sangju 37224, South Korea; Univ Islam Kadiri, Fac Agr, Program Anim Husb, Jl Sersan Suharmaji 38, Kediri 64128, East Java, Indonesia; Res Ctr Anim Husb, Natl Res & Innovat Agcy BRIN, Jl Raya Jakarta Bogor 32, Cibinong 16915, West Java, Indonesia; Wageningen Univ & Res, Dept Anim Sci Specialisat Mol Cell & Organ Functio, Anim Sci, NL-6708 PB Wageningen, Netherlands; Univ Queensland, Sch Agr & Food Sustainabil, Brisbane, Qld, Australia ; Yulianto, Andreas Berny/AFQ-1313-2022; Hidayatik, Nanik/AAI-5882-2021; Baihaqi, Zein/IYJ-0057-2023 56576444100; 57193710262; 57201486014; 58995929200; 58189109000; 58996496400; 56576431600; 57193713403; 57219851669; 57216620095; 57193844875; 57212026505; 57863649900; 58997034500; 57219295438 widya-p-l@fkh.unair.ac.id;moh-a-a-a@fkh.unair.ac.id;nanik.h@fkh.unair.ac.id;aldhiasafira@gmail.com;dyndafebriana24@gmail.com;amadeainas@gmail.com;bernyjulianto@uwks.ac.id;mirnylamid@fkh.unair.ac.id;tabitamarbun@gmail.com;lisnantiertika@gmail.com;zein.ahmad.b@mail.ugm.ac.id;aswinrafif@gmail.com;shendy.kurniawanshendycanadya@wur.nl;erlycasna.br.s.pelawi-2020@fkh.unair.ac.id;a.hasib@uqconnect.edu.au; VETERINARY WORLD VET WORLD 0972-8988 2231-0916 17 2 ESCI AGRICULTURE, DAIRY & ANIMAL SCIENCE;VETERINARY SCIENCES 2024 2 25.0 8.68 2025-05-07 4 12 acidifiers; feed additive; health; performance; probiotic GROWTH-PERFORMANCE; ORGANIC-ACIDS; ADDITIVES; COMBINATION; QUALITY; POTENCY; IMPROVE; DIETS; OILS acidifiers; feed additive; health; performance; probiotic acidifying agent; carbohydrate; citric acid; drinking water; ether; food additive; fumaric acid; organic matter; probiotic agent; protein; Article; ash; biomass production; chemical composition; egg production; egg weight; egg yolk; female; food intake; health; human; nonhuman; nutrient; quail; replication study; systematic review English 2024 2024-02 10.14202/vetworld.2024.462-469 바로가기 바로가기 바로가기 바로가기
Article Expression of claudin 18.2 in poorly cohesive carcinoma and its association with clinicopathologic parameters in East Asian patients Background: Poorly cohesive carcinoma (PCC) is a distinct subtype of gastric cancer with limited therapeutic options. This study investigated claudin (CLDN) 18.2 expression status in PCCs using a 43-13 A clone. Methods: We retrospectively collected 178 consecutive surgically resected stage II-III gastric cancer samples. Tissue microarray blocks were constructed for CLDN18.2 immunohistochemical staining. We studied CLDN18.2 expression and its association with clinicopathologic parameters. Results: CLDN18.2 positivity (defined by >= 75 % of tumor cells showing moderate to strong membranous positivity) was found in 34.8 % of the PCC cases (62/178). Approximately half of the CLDN18.2 positive PCCs demonstrated heterogeneous expression (51.6 %, 32/62). CLDN18.2 positivity was not associated with any clinicopathologic parameters examined. However, CLDN18.2 positivity tended to be more frequent in E-cadherin-positive PCCs (no loss of expression) than in E-cadherin-negative PCCs (loss of expression) (50 % vs. 27.7 %). The CLDN18.2 expression level, represented by the H-score, gradually decreased as the paraffin block storage time increased (P = 0.046). Overall survival and disease-free survival analyses showed no significant difference between CLDN18.2-positive and negative PCCs. Conclusions: A significant portion of surgically resected PCC specimens showed CLDN18.2 positivity. Additionally, since the expression level of CLDN18.2 gradually decreases with increased paraffin block storage time, reflex testing can be considered at the time of the cancer diagnosis. Kim, Moonsik; Kang, Byung Woog; Park, Jihyun; Baek, Jin Ho; Kim, Jong Gwang Kyungpook Natl Univ, Sch Med, Dept Pathol, Daegu, South Korea; Kyungpook Natl Univ, Canc Res Inst, Chilgok Hosp, Sch Med,Dept Oncol Hematol, Daegu, South Korea; Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea Kim, Hye/W-1059-2019 57195918515; 28567838500; 59284110500; 57217075847; 59501049300 jkk21c@knu.ac.kr; PATHOLOGY RESEARCH AND PRACTICE PATHOL RES PRACT 0344-0338 1618-0631 263 SCIE PATHOLOGY 2024 3.2 25.0 0 2025-05-07 1 1 Poorly cohesive carcinoma; CLDN18.2; 43-14A; Immunohistochemistry; Zolbetuximab GASTRIC-CANCER; COLORECTAL-CANCER; OPEN-LABEL; JUNCTION; CHEMOTHERAPY 43–14A; CLDN18.2; Immunohistochemistry; Poorly cohesive carcinoma; Zolbetuximab Adult; Aged; Aged, 80 and over; Asian People; Biomarkers, Tumor; Carcinoma; Claudins; East Asian People; Female; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Stomach Neoplasms; claudin; CLDN18 protein, human; tumor marker; adult; aged; Asian; carcinoma; East Asian; female; human; male; metabolism; middle aged; mortality; pathology; prognosis; retrospective study; stomach tumor; very elderly English 2024 2024-11 10.1016/j.prp.2024.155628 바로가기 바로가기 바로가기 바로가기
Article Nanomaterials in point-of-care diagnostics: Bridging the gap between laboratory and clinical practice The integration of nanomaterials into biosensing technologies represents a paradigm shift in medical diagnostics and environmental monitoring, marking a significant advancement in the field. This comprehensive review examines the role of nanomaterials, such as gold nanoparticles, carbon nanotubes, graphene, and quantum dots, in enhancing the performance of biosensors. These nanomaterials contribute unique physical and chemical properties, including exceptional electrical, optical, and thermal conductivities, which significantly improve the sensitivity, specificity, and versatility of biosensors. The review provides an in-depth analysis of the mechanisms by which these nanomaterials enhance biosensor functionality, including increased surface-to-volume ratio, improved electron transfer rates, and enhanced signal transduction. The practical applications of these advanced biosensors are explored across various domains, including oncology, infectious diseases, diabetes management, cardiovascular health, and neurodegenerative conditions, emphasizing their role in early disease detection, realtime health monitoring, and personalized medicine. Furthermore, the review addresses the critical challenges and limitations facing the field, such as biocompatibility, biofouling, stability, and integration into existing healthcare systems. Strategies to overcome these challenges, including advanced material engineering and novel fabrication techniques, are discussed. The future of nanomaterial-based biosensors is envisioned through the lens of emerging trends and technological innovations. The integration with microfluidics, artificial intelligence, and wearable technology is highlighted as a path toward more personalized, efficient, and accessible healthcare solutions. This review underscores the transformative impact of nanomaterials in biosensing, projecting a future where these advanced technologies play a pivotal role in reshaping diagnostics, patient care, and environmental monitoring, thereby significantly enhancing healthcare and public health outcomes. Jeyaraman, Madhan; Jeyaraman, Naveen; Ramasubramanian, Swaminathan; Balaji, Sangeetha; Iyengar, Karthikeyan. P.; Jain, Vijay Kumar; Rajendran, Ramya Lakshmi; Gangadaran, Prakash Dr MGR Educ & Res Inst, ACS Med Coll & Hosp, Dept Orthopaed, Chennai 600077, Tamil Nadu, India; Govt Med Coll, Dept Orthopaed, Omandurar Govt Estate, Chennai 600002, Tamil Nadu, India; Dr Ram Manohar Lohia Hosp, Atal Bihari Vajpayee Inst Med Sci, Dept Orthopaed, New Delhi 110001, India; Southport & Ormskirk Hosp, Mersey & West Lancashire Teaching NHS Trust, Southport PR8 6PN, England; Kyungpook Natl Univ, Sch Med, Dept Nucl Med, Daegu 41944, South Korea; Kyungpook Natl Univ, Sch Med, Dept Biomed Sci, FOUR KNU Convergence Educ Program Biomed Sci Creat, Daegu 41944, South Korea; Kyungpook Natl Univ, Cardiovasc Res Inst, Daegu, South Korea Gangadaran, Prakash/AAV-3102-2021; Jeyaraman, Madhan/ABB-8464-2020; Bedir, Recep/GYJ-5238-2022; Iyengar, Karthikeyan./S-4529-2019; Ramasubramanian, Swaminathan/ISA-0083-2023; Rajendran, Ramya/AAV-6338-2021 57216926503; 57219306833; 58960264000; 58993757300; 8232199100; 57198886411; 57195318729; 54393130400 naveenjeyaraman@yahoo.com;ramyag@knu.ac.kr;prakashg@knu.ac.kr; PATHOLOGY RESEARCH AND PRACTICE PATHOL RES PRACT 0344-0338 1618-0631 263 SCIE PATHOLOGY 2024 3.2 25.0 0 2025-05-07 0 0 Nanomaterials; Biosensing Technologies; Quantum Dots; Artificial Intelligence; Microfluidics; Wearable Biosensors; Real-Time Analysis; Healthcare Integration NANOSENSORS; BIOSENSOR; NANO Artificial Intelligence; Biosensing Technologies; Healthcare Integration; Microfluidics; Nanomaterials; Quantum Dots; Real-Time Analysis; Wearable Biosensors Biosensing Techniques; Humans; Nanostructures; Point-of-Care Systems; Point-of-Care Testing; nanomaterial; genetic procedures; human; point of care system; point of care testing; procedures English 2024 2024-11 10.1016/j.prp.2024.155685 바로가기 바로가기 바로가기 바로가기
Article Optimizing Secrecy Energy Efficiency in RIS-assisted MISO systems using Deep Reinforcement Learning This article investigates the maximization of secrecy energy efficiency (SEE) in B5G mobile systems where a suite of reconfigurable intelligent surface (RIS) modules is incorporated. Taking into account the location information of legitimate users and eavesdroppers, we formulate the problem as a joint optimization of the phase shifts, physical orientations, and locations of the RIS modules, as well as resource allocation at the base station (BS). The problem is then solved by leveraging a deep reinforcement learning (DRL) approach proposed in this paper. The case study results demonstrate the effectiveness of the proposed scheme in improving the secrecy energy efficiency of communication systems using RIS. Razaq, Mian Muaz; Song, Huanhuan; Peng, Limei; Ho, Pin-Han Kyungpook Natl Univ, Sch Comp Sci & Engn, Daegu 41566, South Korea; Univ Waterloo, Dept Elect & Comp Engn, Waterloo, ON, Canada; Univ Elect Sci & Technol China, Sch Aeronaut & Astronaut, Chengdu 611731, Peoples R China Razaq, Muaz/ACN-8991-2022 57221661906; 56488941700; 7201574271; 7402211578 mianmuaz97@gmail.com;huanhuansong@126.com;auroraplm@knu.ac.kr;p4ho@uwaterloo.ca; COMPUTER COMMUNICATIONS COMPUT COMMUN 0140-3664 1873-703X 217 SCIE ENGINEERING, ELECTRICAL & ELECTRONIC;TELECOMMUNICATIONS;COMPUTER SCIENCE, INFORMATION SYSTEMS 2024 4.3 25.0 1.41 2025-05-07 2 5 Reconfigurable intelligent surface (RIS); Phase shift optimization; Optimal orientation; Eavesdroppers; Secrecy rate; Secrecy energy efficiency; Deep reinforcement learning INTELLIGENT SURFACES; COMMUNICATION; MAXIMIZATION Deep reinforcement learning; Eavesdroppers; Optimal orientation; Phase shift optimization; Reconfigurable intelligent surface (RIS); Secrecy energy efficiency; Secrecy rate Deep learning; Reinforcement learning; Deep reinforcement learning; Eavesdropper; Optimal orientation; Optimisations; Phase shift optimization; Reconfigurable; Reconfigurable intelligent surface; Reinforcement learnings; Secrecy energy efficiency; Secrecy rate; Energy efficiency English 2024 2024-03-01 10.1016/j.comcom.2024.01.020 바로가기 바로가기 바로가기 바로가기
Article Transformer-empowered receiver design of OFDM communication systems With deep learning, we perform channel estimation and signal detection in massive Multiple Input Multiple Output (MIMO)-Orthogonal Frequency Division Multiplexing (OFDM) systems in this paper. Specifically, we design and extend the basic framework of receivers for MIMO-OFDM systems in an end-to-end approach. A Transformer-based MIMO-OFDM receiver called TCD-Receiver is proposed, which introduces a multi-attention mechanism to learn the channel characteristics by introducing a generic and flexible Transformer network structure. The network parameters are updated based on the relationship between the received signal and the original signal, where the final signal information is obtained without explicit channel estimation and the predicted transmit bits are directly output. The experimental results show that the TCD-Receiver proposed can effectively solve the channel distortion and detect the transmitted signals compared with the traditional communication receivers, and its performance can be comparable to that of the traditional OFDM receivers, and it also has obvious advantages in combating the complex and difficult-to-model channel environment as well as the nonlinear interference factors. Yue, Binglei; Qiu, Siyi; Yang, Chun; Peng, Limei; Zhang, Yin Univ Elect Sci & Technol China, Chengdu, Peoples R China; Guangdong Intelligent Robot Inst, Dongguan, Peoples R China; Zhongnan Univ Econ & Law, Wuhan, Peoples R China; Kyungpook Natl Univ, Daegu, South Korea Zhang, Yin/O-2149-2015 57275115800; 59261753900; 57226877494; 7201574271; 56298640900 binglei_yue@std.uestc.edu.cn;qiusiyi@stu.zuel.edu.cn;chunyang0305@std.uestc.edu.cn;auroraplm@knu.ac.kr;yin.zhang.cn@ieee.org; COMPUTER COMMUNICATIONS COMPUT COMMUN 0140-3664 1873-703X 228 SCIE ENGINEERING, ELECTRICAL & ELECTRONIC;TELECOMMUNICATIONS;COMPUTER SCIENCE, INFORMATION SYSTEMS 2024 4.3 25.0 0 2025-05-07 0 1 OFDM receiver; Deep learning; Transformer; Channel estimation; Signal detection CHANNEL ESTIMATION; ACCESS Channel estimation; Deep learning; OFDM receiver; Signal detection; Transformer Channel estimation; Frequency estimation; Communications systems; Deep learning; End to end; Multiple-input multiple-output orthogonal frequency-division multiplexing; Multipleinput multiple-output orthogonal frequency-division multiplexing systems (MIMO-OFDM); Orthogonal frequency division multiplexing receiver; Orthogonal frequency-division multiplexing; Receiver design; Signal's detections; Transformer; Orthogonal frequency division multiplexing English 2024 2024-12-01 10.1016/j.comcom.2024.107960 바로가기 바로가기 바로가기 바로가기
Article Unveiling the role of exosomes as cellular messengers in neurodegenerative diseases and their potential therapeutic implications Exosomes are a subgroup of extracellular vesicles that function as transmitters, allowing cells to communicate more effectively with each other. However, exosomes may have both beneficial and harmful impacts on central nervous system disorders. Hence, the fundamental molecular mechanisms of the origin of illness and its progression are currently being investigated. The involvement of exosomes in the origin and propagation of neurodegenerative illness has been demonstrated recently. Exosomes provide a representation of the intracellular environment since they include various essential bioactive chemicals. The latest studies have demonstrated that exosomes transport several proteins. Additionally, these physiological vesicles are important in the regeneration of nervous tissue and the healing of neuronal lesions. They also offer a microenvironment to stimulate the conformational variation of concerning proteins for aggregation, resulting in neurodegenerative diseases. The biosynthesis, composition, and significance of exosomes as extracellular biomarkers in neurodegenerative disorders are discussed in this article, with a particular emphasis on their neuroprotective effects. Ashique, Sumel; Kumar, Nitish; Mishra, Neeraj; Muthu, Sathish; Rajendran, Ramya Lakshmi; Chandrasekaran, Balakumar; Obeng, Brenya Francis; Hong, Chae Moon; Krishnan, Anand; Ahn, Byeong-Cheol; Gangadaran, Prakash Bengal Coll Pharmaceut Sci & Res, Dept Pharmaceut, Durgapur 713212, W Bengal, India; Lovely Profess Univ, Sch Pharmaceut Sci, Phagwara 144411, Punjab, India; SRM Inst Sci & Technol, SRM Modinagar Coll Pharm, Delhi NCR Campus, Ghaziabad 201204, Uttar Pradesh, India; Amity Univ Madhya Pradesh AUMP, Amity Inst Pharm, Gwalior 474005, Madhya Pradesh, India; Orthopaed Res Grp, Dept Orthopaed, Coimbatore 641045, Tamil Nadu, India; Karpagam Acad Higher Educ, Fac Engn, Dept Biotechnol, Coimbatore 641021, Tamil Nadu, India; Kyungpook Natl Univ, Dept Nucl Med, Sch Med, Daegu 41944, South Korea; Philadelphia Univ, Fac Pharm, POB 1, Amman 19392, Jordan; Univ Cape Coast, Coll Hlth & Allied Sci, Fac Sci, Sch Med Sci, Cape Coast, Ghana; Univ Free State, Fac Hlth Sci, Sch Pathol, Dept Chem Pathol, ZA-9300 Bloemfontein, South Africa; Kyungpook Natl Univ, Sch Med, Dept Biomed Sci, FOUR KNU Convergence Educ Program Biomed Sci Creat, Daegu 41944, South Korea; Kyungpook Natl Univ Hosp, Dept Nucl Med, Daegu 41944, South Korea Krishnan, Anand/C-5178-2015; Mishra, Neeraj/AAR-3299-2021; Muthu, Sathish/G-5756-2018; ObengBrenya, Francis/LDG-3528-2024; Rajendran, Ramya/AAV-6338-2021; Gangadaran, Prakash/AAV-3102-2021 57219283396; 57222165001; 57216949872; 57217850874; 57195318729; 36614134400; 59215493900; 37050876700; 57488883300; 7202791511; 54393130400 Krishnana1@ufs.ac.za;abc2000@knu.ac.kr;prakashg@knu.ac.kr; PATHOLOGY RESEARCH AND PRACTICE PATHOL RES PRACT 0344-0338 1618-0631 260 SCIE PATHOLOGY 2024 3.2 25.0 1.5 2025-05-07 6 8 Exosomes; Biomarkers; Neurodegenerative diseases; Exosomal therapeutics; Neuroprotective effects EXTRACELLULAR VESICLES; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; AMYLOID-BETA; PARKINSONS-DISEASE; SYSTEMIC INJECTION; NEURONAL EXOSOMES; BLOOD EXOSOMES; SPINAL-CORD; HUNTINGTIN Biomarkers; Exosomal therapeutics; Exosomes; Neurodegenerative diseases; Neuroprotective effects Animals; Biomarkers; Cell Communication; Exosomes; Humans; Neurodegenerative Diseases; biological marker; biological marker; biosynthesis; central nervous system disease; degenerative disease; exosome; human; microenvironment; nerve lesion; nervous tissue; neuroprotection; nonhuman; review; animal; cell communication; metabolism; pathology; physiology English 2024 2024-08 10.1016/j.prp.2024.155451 바로가기 바로가기 바로가기 바로가기
Article Antimicrobial Use and Carbapenem-Resistant Enterobacterales in Korea: A Nationwide Case-Control Study With Propensity Score Matching Background: Nationwide research on the association between carbapenem-resistant Enterobacterales (CREs) and antibiotic use is limited. Methods: This nested case-control study analyzed Korean National Health Insurance claims data from April 2017 to April 2019. Based on the occurrence of CRE, hospitalized patients aged >= 18 years were classified into CRE (cases) and control groups. Propensity scores based on age, sex, modified Charlson comorbidity score, insurance type, long-term care facility, intensive care unit stay, and acquisition of vancomycin-resistant Enterococci were used to match the case and control groups (1:3). Results: After matching, the study included 6,476 participants (1,619 cases and 4,857 controls). Multivariable logistic regression analysis revealed that the utilization of broad-spectrum antibiotics, such as piperacillin/tazobactam (adjusted odds ratio [aOR], 2.178; 95% confidence interval [CI], 1.829-2.594), third/fourth generation cephalosporins (aOR, 1.764; 95% CI, 1.514-2.056), and carbapenems (aOR, 1.775; 95% CI, 1.454-2.165), as well as the presence of comorbidities (diabetes [aOR, 1.237; 95% CI, 1.061-1.443], hemiplegia or paraplegia [aOR, 1.370; 95% CI, 1.119-1.679], kidney disease [aOR, 1.312; 95% CI, 1.105-1.559], and liver disease [aOR, 1.431; 95% CI, 1.073-1.908]), were significantly associated with the development of CRE. Additionally, the CRE group had higher mortality (8.33 vs. 3.32 incidence rate per 100 person-months, P < 0.001) and a total cost of healthcare utilization per person-month (15,325,491 +/- 23,587,378 vs. 5,263,373 +/- 14,070,118 KRW, P < 0.001) than the control group. Conclusion: The utilization of broad-spectrum antibiotics and the presence of comorbidities are associated with increasing development of CRE. This study emphasizes the importance of antimicrobial stewardship in reducing broad-spectrum antibiotic use and CRE disease burden in Korea. Kwon, Ki Tae; Kim, Yoonjung; Kim, Shin-Woo; Chang, Hyun-Ha; Hwang, Soyoon; Bae, Sohyun; Nam, Eunkyung Kyungpook Natl Univ Hosp, Kyungpook Natl Univ, Sch Med, 130 Dongdeok Ro, Daegu 41944, South Korea Kim, Wonhee/AAA-1074-2021; Hwang, Soyoon/HHM-5762-2022; Kim, Hanjin/KYP-2633-2024; Kim, Tae-You/J-2750-2012 9733850500; 57203160508; 8710731500; 7407521688; 57203160675; 57219699506; 58121908200 ksw2kms@knu.ac.kr; JOURNAL OF KOREAN MEDICAL SCIENCE J KOREAN MED SCI 1011-8934 1598-6357 39 14 SCIE MEDICINE, GENERAL & INTERNAL 2024 2.3 25.2 0 2025-04-16 0 0 Carbapenems; Carbapenemase; Risk Factors; Antimicrobial Stewardship RISK-FACTORS; ESCHERICHIA-COLI; ACQUISITION; EPIDEMIOLOGY; CARE; PREVALENCE; IMPACT Antimicrobial Stewardship; Carbapenemase; Carbapenems; Risk Factors Anti-Bacterial Agents; Carbapenems; Case-Control Studies; Enterobacteriaceae Infections; Humans; Propensity Score; Republic of Korea; antiinfective agent; carbapenem derivative; case control study; Enterobacteriaceae infection; human; propensity score; South Korea English 2024 2024-04-15 10.3346/jkms.2024.39.e132 바로가기 바로가기 바로가기 바로가기
Article Characteristics According to Frailty Status Among Older Korean Patients With Hypertension Background: As the prevalence of hypertension increases with age and the proportion of the older population is also on the rise, research on the characteristics of older hypertensive patients and the importance of frailty is necessary. This study aimed to identify clinical characteristics of older hypertension in Korea and to investigate these characteristics based on frailty status. Methods: The HOW to Optimize eLDerly systolic BP (HOWOLD-BP) is a prospective, multicenter, open-label, randomized clinical trial that aims to compare intensive (target systolic blood pressure [SBP] = 65 years. Data were analyzed through a screening assessment of 2,085 patients recruited from 11 university hospitals. Demographic, functional (physical and cognitive), medical history, laboratory data, quality of life, and medication history of antihypertensive drugs were assessed. Results: The mean age was 73.2 years (standard deviation +/- 5.60), and 48.0% (n = 1,001) were male. Prevalent conditions included dyslipidemia (66.5%), obesity (body mass index >= 25 kg/m(2), 53.6%), and diabetes (28.9%). Dizziness and orthostatic hypotension were self-reported by 1.6% (n = 33) and 1.2% (n = 24), respectively. The majority of patients were on two antihypertensive drugs (48.4%), while 27.5% (n = 574) and 20.8% (n = 433) were on 1 and 3 antihypertensive medications, respectively. Frail to pre-frail patients were older and also tended to have dependent instrumental activities of daily living, slower gait speed, weaker grip strength, lower quality of life, and lower cognitive function. The frail to pre-frail group reported more dizziness (2.6% vs. 1.2%, P < 0.001) and had concerning clinical factors, including lower glomerular filtration rate, more comorbidities such as diabetes, stroke, and a history of admission. Frail to pre-frail older hypertensive patients used slightly more antihypertensive medications than robust older hypertensive patients (1.95 vs. 2.06, P = 0.003). Pre-frail to frail patients often chose beta-blockers as a third medication over diuretics. Conclusion: This study described the general clinical characteristics of older hypertensive patients in Korea. Frail hypertensive patients face challenges in achieving positive clinical outcomes because of multifactorial causes: they are older, have more morbidities, decreased function, lower quality of life and cognitive function, and take more antihypertensive medications. Therefore, it is essential to comprehensively evaluate and monitor disease-related or drug-related adverse events more frequently during regular check-ups, which is necessary for pre-frail to frail older patients with hypertension. Choi, Jung-Yeon; Lee, Hae-Young; Lee, Ju-Hee; Hong, Youjin; Park, Sue K.; Ryu, Dong Ryeol; Lee, Jang Hoon; Hwang, Seokjae; Kim, Kye Hun; Lee, Sun Hwa; Kim, Song-Yi; Park, Jae-Hyeong; Kim, Sang-Hyun; Kim, Hack-Lyoung; Choi, Jung Hyun; Kim, Cheol-Ho; Cho, Myeong-Chan; Kim, Kwang-il Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Chungbuk Natl Univ, Coll Med, Dept Internal Med, Cheongju, South Korea; Chungbuk Natl Univ Hosp, Dept Cardiol, Cheongju, South Korea; Chungbuk Natl Univ Hosp, Cardiocerebrovascular Ctr, Cheongju, South Korea; Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; Seoul Natl Univ, Canc Res Inst, Seoul, South Korea; Seoul Natl Univ, Grad Sch, Integrated Major Innovat Med Sci, Seoul, South Korea; Kangwon Natl Univ, Kangwon Natl Univ Hosp, Sch Med, Dept Internal Med,Div Cardiol, Chunchon, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea; Gyeongsang Natl Univ, Gyeongsang Natl Univ Hosp, Coll Med, Dept Internal Med, Jinju, South Korea; Chonnam Natl Univ, Chonnam Natl Univ Hosp, Med Sch, Dept Cardiovasc Med, Gwangju, South Korea; Jeonbuk Natl Univ, Jeonbuk Natl Univ Hosp, Med Sch, Dept Internal Med,Div Cardiol, Jeonju, South Korea; Jeju Natl Univ Hosp, Dept Internal Med, Div Cardiol, Jeju, South Korea; Chungnam Natl Univ, Chungnam Natl Univ Hosp, Coll Med, Dept Internal Med.Div Cardiol, Daejeon, South Korea; Seoul Metropolitan Govt Seoul Natl Univ, Boramae Med Ctr, Dept Internal Med, Div Cardiol, Seoul, South Korea; Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Med Res Inst,Dept Internal Med,Div Cardiol, Busan, South Korea; Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Internal Med, 82 Gumi Ro173 Beon Gil, Seongnam 13620, South Korea Park, Jae-Hyeong/AAD-9015-2021; Kim, Song-Yi/JAC-5358-2023; Kim, Cheol/J-5444-2012; lee, sun hwa/R-1431-2019 56509684100; 56151235500; 57204073070; 57885302400; 8085325400; 57201809600; 54581258000; 36007319200; 56150430800; 57887827800; 35740671300; 36063048400; 49663680000; 17135448100; 56399550000; 58179428500; 58092080500; 57193847032 kikim907@snu.ac.kr; JOURNAL OF KOREAN MEDICAL SCIENCE J KOREAN MED SCI 1011-8934 1598-6357 39 10 SCIE MEDICINE, GENERAL & INTERNAL 2024 2.3 25.2 0.94 2025-04-16 1 1 Frailty; Hypertension; Older; Elderly SYSTEMATIC ANALYSIS; RISK-FACTORS; WEIGHT-LOSS; FACT SHEET; VALIDATION; COUNTRIES; DISEASE; VERSION; BURDEN; ADULTS Elderly; Frailty; Hypertension; Older Activities of Daily Living; Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus; Dizziness; Female; Frailty; Humans; Hypertension; Male; Prospective Studies; Quality of Life; Republic of Korea; antihypertensive agent; aged; blood pressure; clinical trial; complication; controlled study; daily life activity; diabetes mellitus; dizziness; female; frailty; human; hypertension; male; multicenter study; prospective study; quality of life; randomized controlled trial; South Korea English 2024 2024-03-18 10.3346/jkms.2024.39.e84 바로가기 바로가기 바로가기 바로가기
Article Characteristics of Pediatric Ulcerative Colitis at Diagnosis in Korea: Results From a Multicenter, Registry-Based, Inception Cohort Study Background: We aimed to investigate the characteristics of pediatric ulcerative colitis (UC) at diagnosis in Korea. Methods: This was a multicenter, registry-based, inception cohort study conducted in Korea between 2021 and 2023. Children and adolescents newly diagnosed with UC < 18 years were included. Baseline clinicodemographics, results from laboratory, endoscopic exams, and Paris classification factors were collected, and associations between factors at diagnosis were investigated. Results: A total 205 patients with UC were included. Male-to-female ratio was 1.59:1, and the median age at diagnosis was 14.7 years (interquartile range 11.9-16.2). Disease extent of E1 comprised 12.2% (25/205), E2 24.9% (51/205), E3 11.2% (23/205), and E4 51.7% (106/205) of the patients. S1 comprised 13.7% (28/205) of the patients. The proportion of patients with a disease severity of S1 was significantly higher in patients with E4 compared to the other groups (E1: 0% vs. E2: 2% vs. E3: 0% vs. E4: 24.5%, P < 0.001). Significant differences between disease extent groups were also observed in Pediatric Ulcerative Colitis Activity Index (median 25 vs. 35 vs. 40 vs. 45, respectively, P < 0.001), hemoglobin (median 13.5 vs. 13.2 vs. 11.6 vs. 11.4 g/dL, respectively, P < 0.001), platelet count (median 301 vs. 324 vs. 372 vs. 377 x 10(3)/mu L, respectively, P = 0.001), C-reactive protein (median 0.05 vs. 0.10 vs. 0.17 vs. 0.38 mg/dL, respectively, P < 0.001), and Ulcerative Colitis Endoscopic Index of Severity (median 4 vs. 4 vs. 4 vs. 5, respectively, P = 0.006). No significant differences were observed in factors between groups divided according to sex and diagnosis age. Conclusion: This study represents the largest multicenter pediatric inflammatory bowel disease cohort in Korea. Disease severity was associated with disease extent in pediatric patients with UC at diagnosis. Lim, Jin Gyu; Kang, Ben; Oh, Seak Hee; Ryoo, Eell; Kim, Yu Bin; Choe, Yon Ho; Lee, Yeoun Joo; Shin, Minsoo; Yang, Hye Ran; Kim, Soon Chul; Lee, Yoo Min; Koh, Hong; Park, Ji Sook; Choi, So Yoon; Jeong, Su Jin; Lee, Yoon; Chang, Ju Young; Kim, Tae Hyeong; Shim, Jung Ok; Moon, Jin Soo Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Pediat, Daegu, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pediat, Seoul, South Korea; Gachon Univ, Gil Med Ctr, Dept Pediat, Incheon, South Korea; Ajou Univ, Sch Med, Dept Pediat, Suwon, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea; Pusan Natl Univ, Sch Med, Dept Pediat, Childrens Hosp, Yangsan, South Korea; Korea Univ, Dept Pediat, Med Ctr, Ansan Hosp, Seoul, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Pediat, Seongnam, South Korea; Jeonbuk Natl Univ, Jeonbuk Natl Univ Hosp, Med Sch, Jeonju, South Korea; Soonchunhyang Univ, Coll Med, Bucheon Hosp, Dept Pediat, Bucheon, South Korea; Yonsei Univ, Severance Childrens Hosp, Coll Med, Div Gastroenterol Hepatol & Nutr,Dept Pediat, Seoul, South Korea; Gyeongsang Natl Univ, Coll Med, Dept Pediat, Jinju, South Korea; Kosin Univ, Coll Med, Dept Pediat, Gospel Hosp, Pusan 602702, South Korea; CHA Univ, Sch Med, CHA Bundang Med Ctr, Dept Pediat, Seongnam, South Korea; Korea Univ, Dept Pediat, Med Ctr, Anam Hosp, Seoul, South Korea; Seoul Natl Univ, Dept Pediat, Boramae Med Ctr, Seoul Metropolitan Govt, Seoul, South Korea; Kyung Hee Univ Hosp Gangdong, Dept Pediat, Seoul, South Korea; Korea Univ, Coll Med, Dept Pediat, Guro Hosp, 148 Gurodong Ro, Seoul 08308, South Korea Chang, Ju/J-5631-2012; 康, 奔/JMQ-0812-2023; Yang, Hye/J-5533-2012; Shin, Min Soo/LKK-2292-2024; Lee, Chang/AAI-1012-2020; Hyeong, Kim/AAI-4428-2020; Lee, Yong Jae/GLR-4153-2022 58748860500; 57194823199; 36141915600; 19837506900; 57212382905; 21333712100; 34877162300; 57331053900; 57049781100; 36087407700; 55588928200; 35789948700; 35485228600; 57207282105; 57192812021; 55588945800; 7601549478; 57604724000; 57022898300; 25646123100 shimjo@korea.ac.kr;mjschj@snu.ac.kr; JOURNAL OF KOREAN MEDICAL SCIENCE J KOREAN MED SCI 1011-8934 1598-6357 39 49 SCIE MEDICINE, GENERAL & INTERNAL 2024 2.3 25.2 0 2025-05-07 2 2 Ulcerative Colitis; Child; Korea INFLAMMATORY-BOWEL-DISEASE; NATURAL-HISTORY; EARLY-ONSET; MANAGEMENT; CONSENSUS Child; Korea; Ulcerative Colitis Adolescent; Child; Cohort Studies; Colitis, Ulcerative; Female; Humans; Male; Pediatric ulcerative colitis; Registries; Republic of Korea; Severity of Illness Index; adolescent; child; clinical trial; cohort analysis; diagnosis; female; human; male; multicenter study; pathology; register; severity of illness index; South Korea; ulcerative colitis English 2024 2024-12-23 10.3346/jkms.2024.39.e303 바로가기 바로가기 바로가기 바로가기
Article Consensus Statements on the Definition, Classification, and Diagnostic Tests for Tinnitus: A Delphi Study Conducted by the Korean Tinnitus Study Group Background: Tinnitus is a bothersome condition associated with various symptoms. However, the mechanisms of tinnitus are still uncertain, and a standardized assessment of the diagnostic criteria for tinnitus is required. We aimed to reach a consensus on diagnosing tinnitus with professional experts by conducting a Delphi study with systematic review of the literature. Methods: Twenty-six experts in managing tinnitus in Korea were recruited, and a two-round modified Delphi study was performed online. The experts evaluated the level of agreement of potential criteria for tinnitus using a scale of 1-9. After the survey, a consensus meeting was held to establish agreement on the results obtained from the Delphi process. Consensus was defined when over 70% of the participants scored 7-9 (agreement) and fewer than 15% scored 1-3 (disagreement). To analyze the responses of the Delphi survey, the content validity ratio and Kendall's coefficient of concordance were evaluated. Results: Consensus was reached for 22 of the 38 statements. For the definition of tinnitus, 10 out of 17 statements reached consensus, with three statements achieving complete agreement including; 1) Tinnitus is a conscious perception of an auditory sensation in the absence of a corresponding external stimulus, 2) Tinnitus can affect one's quality of life, and 3) Tinnitus can be associated with hearing disorders including sensorineural hearing loss, vestibular schwannoma, Meniere's disease, otosclerosis, and others. For the classification of tinnitus, 11 out of 18 statements reached consensus. The participants highly agreed with statements such as; 1) Vascular origin is expected in pulse-synchronous tinnitus, and 2) Tinnitus can be divided into acute or chronic tinnitus. Among three statements on the diagnostic tests for tinnitus only Statement 3, "There are no reliable biomarkers for sensory or emotional factors of tinnitus." reached consensus. All participants agreed to perform pure-tone audiometry and tinnitus questionnaires, including the Tinnitus Handicap Inventory and Tinnitus Questionnaire. Conclusion: We used a modified Delphi method to establish a consensus-based definition, a classification, and diagnostic tests for tinnitus. The expert panel reached agreement for several statements, with a high level of consensus. This may provide practical information for clinicians in managing tinnitus. Choo, Oak-Sung; Kim, Hantai; Lee, Seung Jae; Kim, So Young; Lee, Kyu-Yup; Lee, Ho Yun; Moon, In Seok; Seo, Jae-Hyun; Rah, Yoon Chan; Song, Jae-Jun; Nam, Eui-Cheol; Park, Shi Nae; Song, Jae-Jin; Joon Shim, Hyun Hallym Univ, Coll Med, Kangnam Sacred Heart Hosp, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea; Konyang Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Daejeon, South Korea; Inje Univ, Coll Med, Ilsan Paik Hosp, Dept Otorhinolaryngol, Goyang, South Korea; CHA Univ, CHA Bundang Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Seongnam, South Korea; Kyungpook Natl Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Daegu, South Korea; Ewha Womans Univ, Coll Med, Dept Otolaryngol Head & Neck Surg, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea; Korea Univ, Ansan Hosp, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Ansan, South Korea; Korea Univ, Guro Hosp, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea; Kangwon Natl Univ, Coll Med, Dept Otorhinolaryngol, Chunchon, South Korea; Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seongnam, South Korea; Seoul Natl Univ, Med Res Ctr, Sensory Organ Res Inst, Seoul, South Korea; Eulji Univ, Sch Med, Nowon Eulji Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, 68 Hangeulbiseok Ro, Seoul 01830, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Otorhinolaryngol Head & Neck Surg, 166 Gumi Ro, Seongnam 13620, South Korea ; Kim, So-Young/JFS-7698-2023; Song, Jae-Jin/E-4633-2017; Lee, Doh Young/GLR-9586-2022; Kim, Hyung/J-5451-2012 55579114100; 57221994950; 57202851802; 35484438400; 22135779500; 57189579843; 55953868500; 48161796300; 36978238900; 55574123314; 7005824282; 7501826944; 56294178300; 35171593100 jjsong96@snubh.org;eardoc11@naver.com;jjsong96@gmail.com; JOURNAL OF KOREAN MEDICAL SCIENCE J KOREAN MED SCI 1011-8934 1598-6357 39 5 SCIE MEDICINE, GENERAL & INTERNAL 2024 2.3 25.2 1.88 2025-04-16 3 3 Tinnitus; Delphi Study; Systematic Review PREVALENCE; MECHANISMS; TIME Delphi Study; Systematic Review; Tinnitus Delphi Technique; Diagnostic Tests, Routine; Humans; Quality of Life; Republic of Korea; Tinnitus; Delphi study; diagnostic test; human; quality of life; South Korea; tinnitus English 2024 2024-02-05 10.3346/jkms.2024.39.e49 바로가기 바로가기 바로가기 바로가기
Article Efficacy of combining aspirin with hydroxychloroquine in pregnancies at high risk for pre-eclampsia: a prospective, multicentre, open-label, single-arm clinical trial, investigator-initiated study (HUGS study) Introduction The use of hydroxychloroquine (HCQ) during pregnancies complicated by systemic lupus erythematosus or refractory antiphospholipid antibody syndrome has demonstrated a significant ability to prevent pre-eclampsia (PE). As such, the potential for the administration of HCQ to prevent PE in other high-risk pregnancies is an important clinical research agenda among maternal and fetal medicine specialists. Mechanistically, the anti-inflammatory and immunomodulatory effects of HCQ can offer vascular protection and inhibit the placental dysfunction-associated thrombotic changes underlying the pathophysiology of PE, fetal growth restriction (FGR) and fetal death in utero (FDIU). Placenta-mediated complications exhibit a distinctive overlapping syndrome between pregnancies, and low-dose aspirin is the only prevention method currently in use. This study investigated the effects of improvements in outcomes with HCQ administration in high-risk pregnancies complicated by a previous experience of PE, FGR or FDIU.Methods and analysis This multicentre, open-label, single-arm trial commenced on 31 May 2022, in three tertiary hospitals in Korea. Pregnant women with a prior history of PE, FGR or FDIU are eligible to participate. This single-arm study set the previous study with the most similar inclusion criteria, aspirin dose and drug administration period as the comparison group. The required sample size was determined to be 58, with an expected dropout rate of 10%.Ethics and dissemination This study protocol was approved by the following institutions and committees: Institutional Review Boards of Chung-Ang University Gwangmyeong Hospital (2304-082-056), Samsung Medical Center (2021-11-087-003) and Kyungpook National University Chilgok Hospital (2021-06-005-006) and the Ministry of Food and Drug Safety. The results will be disseminated to the general public, grant funder, maternal-fetal medicine specialists and other researchers.Trial registration number NCT05287321. Kim, Yoo-Min; Seong, Jisu; Kim, Ji Hoi; Nam, Gina; Kim, Gwang jun; Cha, Hyun-Hwa; Seong, Won Joon; Sung, Ji-Hee; Choi, Suk-Joo; Oh, Soo-Young; Roh, Cheong-Rae Chung Ang Univ, Gwangmyeong Hosp, Dept Obstet & Gynecol, Gwangmyeong, South Korea; Chung Ang Univ Hosp, Dept Obstet & Gynecol, Seoul, South Korea; Kyungpook Natl Univ, Dept Obstet & Gynecol, Chilgok Hosp, Daegu, South Korea; Samsung Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea Kim, Yoo-min/AAZ-6413-2020 57191974142; 57205467180; 57225069837; 57222320563; 20433722300; 37033517800; 26656946000; 56347330000; 55601869400; 55601514300; 7003492919 shygirl1227@naver.com;jsseong0323@gmail.com;fathoi@naver.com;whyohyou@daum.net;gjkim@cau.ac.kr;chh9861@knu.ac.kr;wjseong@knu.ac.kr;obgysung@gmail.com;drmaxmix.choi@samsung.com;ohsymd@skku.edu;crroh@skku.edu; BMJ OPEN BMJ OPEN 2044-6055 14 12 SCIE MEDICINE, GENERAL & INTERNAL 2024 2.3 25.2 0 2025-05-07 0 1 Fetal medicine; Maternal medicine; PREVENTIVE MEDICINE; Pregnant Women LOW-DOSE ASPIRIN; GROWTH RESTRICTION; PREVENTION; HYPERTENSION; CHLOROQUINE; MANAGEMENT Adult; Aspirin; Drug Therapy, Combination; Female; Fetal Growth Retardation; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy, High-Risk; Prospective Studies; acetylsalicylic acid; hydroxychloroquine; acetylsalicylic acid; hydroxychloroquine; adult; Article; clinical outcome; controlled study; female; fetus death; high risk pregnancy; human; intrauterine growth retardation; low drug dose; major clinical study; medication compliance; multicenter study; preeclampsia; pregnancy; pregnancy outcome; prematurity; prospective study; South Korea; clinical trial; combination drug therapy; drug therapy; high risk pregnancy; preeclampsia; pregnancy; prevention and control English 2024 2024-12-10 10.1136/bmjopen-2023-081610 바로가기 바로가기 바로가기 바로가기
Editorial Material For the Universal Right to Access Quality End-of-Life Care in Korea: Broadening Our Perspective After the 2018 Life-Sustaining Treatment Decisions Act Park, Hye Yoon; Kim, Min Sun; Yoo, Shin Hye; Lee, Jung; Song, In Gyu; Jeon, So Yeon; Choi, Eun Kyung Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Psychiat, Coll Med, Seoul, South Korea; Seoul Natl Univ Hosp, Ctr Palliat Care & Clin Ethics, Seoul, South Korea; Seoul Natl Univ Hosp, Ctr Integrat Care Hub, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Pediat, Seoul, South Korea; Yonsei Univ, Severance Childrens Hosp, Dept Pediat, Seoul, South Korea; Chungnam Natl Univ Hosp, Dept Psychiat, Daejeon, South Korea; Chungnam Natl Univ, Coll Med, Dept Psychiat, Daejeon, South Korea; Kyungpook Natl Univ, Sch Med, Dept Med Humanities & Med Educ, Daegu, South Korea; Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Psychiat, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea ; choi, eunkyung/JUF-8150-2023; Kim, Seonghwan/AAZ-1679-2021 57189505933; 55568531722; 57192955525; 57304883900; 56498470700; 57190943515; 57391706800 hypark@snu.ac.kr; JOURNAL OF KOREAN MEDICAL SCIENCE J KOREAN MED SCI 1011-8934 1598-6357 39 12 SCIE MEDICINE, GENERAL & INTERNAL 2024 2.3 25.2 0.94 2025-04-16 2 2 Decision Making; Hospice Care; Humans; Korea; Republic of Korea; Terminal Care; Withholding Treatment; decision making; hospice care; human; Korea; South Korea; terminal care; treatment withdrawal English 2024 2024-04-01 10.3346/jkms.2024.39.e123 바로가기 바로가기 바로가기 바로가기
Article Impact of COVID-19 Infection and Its Association With Previous Vaccination in Patients With Myasthenia Gravis in Korea: A Multicenter Retrospective Study Background: During the coronavirus disease 2019 (COVID-19) pandemic, patients with myasthenia gravis (MG) were more susceptible to poor outcomes owing to respiratory muscle weakness and immunotherapy. Several studies conducted in the early stages of the COVID-19 pandemic reported higher mortality in patients with MG compared to the general population. This study aimed to investigate the clinical course and prognosis of COVID-19 in patients with MG and to compare these parameters between vaccinated and unvaccinated patients in South Korea. Methods: This multicenter, retrospective study, which was conducted at 14 tertiary hospitals in South Korea, reviewed the medical records and identified MG patients who contracted COVID-19 between February 2022 and April 2022. The demographic and clinical characteristics associated with MG and vaccination status were collected. The clinical outcomes of COVID-19 infection and MG were investigated and compared between the vaccinated and unvaccinated patients. Results: Ninety-two patients with MG contracted COVID-19 during the study. Nine (9.8%) patients required hospitalization, 4 (4.3%) of whom were admitted to the intensive care unit. Seventy-five of 92 patients were vaccinated before contracting COVID-19 infection, and 17 were not. During the COVID-19 infection, 6 of 17 (35.3%) unvaccinated patients were hospitalized, whereas 3 of 75 (4.0%) vaccinated patients were hospitalized ( P < 0.001). The frequencies of ICU admission and mechanical ventilation were significantly lower in the vaccinated patients than in the unvaccinated patients ( P = 0.019 and P = 0.032, respectively). The rate of MG deterioration was significantly lower in the vaccinated patients than in the unvaccinated patients ( P = 0.041). Logistic regression after weighting revealed that the risk of hospitalization and MG deterioration after COVID-19 infection was significantly lower in the vaccinated patients than in the unvaccinated patients. Conclusion: This study suggests that the clinical course and prognosis of patients with MG who contracted COVID-19 during the dominance of the omicron variant of COVID-19 may be milder than those at the early phase of the COVID-19 pandemic when vaccination was unavailable. Vaccination may reduce the morbidity of COVID-19 in patients with MG and effectively prevent MG deterioration induced by COVID-19 infection. Han, Hee Jo; Kim, Seung Woo; Kim, Hyunjin; So, Jungmin; Lee, Eun-Jae; Lim, Young -Min; Lee, Jung Hwan; Lee, Myung Ah; Kim, Byung-Jo; Baek, Seol-Hee; Lee, Hyung-Soo; Sohn, Eunhee; Kim, Sooyoung; Park, Jin-Sung; Kang, Minsung; Park, Hyung Jun; Yoon, Byeol-A; Kim, Jong Kuk; Seok, Hung Youl; Kim, Sohyeon; Min, Ju-Hong; Chung, Yeon Hak; Cho, Jeong Hee; Kim, Jee-Eun; Oh, Seong-il; Shin, Ha Young Yonsei Univ, Dept Neurol, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurol, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Neurol, Seoul, South Korea; Catholic Univ Korea, Uijeongbu St Marys Hosp, Coll Med, Dept Neurol, Seoul, South Korea; Korea Univ, Anam Hosp, Dept Neurol, Seoul, South Korea; Seoul Med Ctr, Dept Neurol, Seoul, South Korea; Chungnam Natl Univ, Chungnam Natl Univ Hosp, Coll Med, Dept Neurol, Daejeon, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Neurol, Daegu, South Korea; Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Neurol, Seoul, South Korea; Dong A Univ, Coll Med, Dept Neurol, Pusan, South Korea; Keimyung Univ, Sch Med, Dept Neurol, Dongsan Hosp, Daegu, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul, South Korea; Natl Hlth Insurance Serv Ilsan Hosp, Dept Neurol, Goyang, South Korea; Ewha Womans Univ, Coll Med, Dept Neurol, Seoul Hosp, Seoul, South Korea; Kyung Hee Univ, Coll Med, Kyung Hee Univ Hosp, Dept Neurol, Seoul, South Korea; Korea Univ, Dept Neurol, Ansan Hosp, Ansan, South Korea Kim, Seung Woo/HOF-6634-2023; Oh, Seong-il/A-8790-2019; Kim, Byung-Jo/A-5943-2012; Kim, Hyunjin/MDS-5282-2025; Seok, Hung Youl/HZI-4365-2023; Chung, Yeon Hak/KDN-2752-2024 57219466490; 57210940345; 57843819900; 57957614900; 35409781500; 36869623200; 55922634700; 35227488700; 25626766200; 57164292800; 57273295400; 35890331200; 57225184791; 44061744500; 57719257600; 55989522800; 57141756000; 54580955800; 24472118000; 57214724357; 8235117900; 57555089800; 55413517800; 36663634500; 47861459800; 57284462800 hayshin@yuhs.ac; JOURNAL OF KOREAN MEDICAL SCIENCE J KOREAN MED SCI 1011-8934 1598-6357 39 18 SCIE MEDICINE, GENERAL & INTERNAL 2024 2.3 25.2 0.94 2025-04-16 2 2 Myasthenia Gravis; COVID-19 Infection; Vaccination; Outcomes; Worsening CORONAVIRUS DISEASE 2019 COVID-19 Infection; Myasthenia Gravis; Outcomes; Vaccination; Worsening Adult; Aged; COVID-19; COVID-19 Vaccines; Female; Hospitalization; Humans; Intensive Care Units; Male; Middle Aged; Myasthenia Gravis; Prognosis; Republic of Korea; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Vaccination; SARS-CoV-2 vaccine; adult; aged; artificial ventilation; clinical trial; complication; coronavirus disease 2019; female; hospitalization; human; intensive care unit; isolation and purification; male; middle aged; multicenter study; myasthenia gravis; prognosis; retrospective study; Severe acute respiratory syndrome coronavirus 2; South Korea; vaccination English 2024 2024-05-13 10.3346/jkms.2024.39.e150 바로가기 바로가기 바로가기 바로가기
페이지 이동:

논문 데이터 용어 설명

용어 설명
WoS Web of Science. Clarivate Analytics에서 제공하는 학술 데이터베이스입니다. 해당 논문이 WoS에 수록되어 있는지 여부를 표시합니다 (○: 수록됨).
SCOPUS Elsevier에서 제공하는 세계 최대 규모의 초록 및 인용 데이터베이스입니다. 해당 논문이 SCOPUS에 수록되어 있는지 여부를 표시합니다 (○: 수록됨).
Document Type 문헌의 유형을 나타냅니다. Article(원저), Review(리뷰), Proceeding Paper(학회논문), Editorial Material(편집자료), Letter(레터) 등으로 분류됩니다.
Title 논문의 제목입니다.
Abstract 논문의 초록(요약)입니다. 연구의 목적, 방법, 결과, 결론을 간략히 요약한 내용입니다.
Authors 논문의 저자 목록입니다. 공동 저자가 여러 명인 경우 세미콜론(;)으로 구분됩니다.
Affiliation 저자들의 소속 기관 정보입니다. 대학, 연구소, 기업 등 저자가 소속된 기관명이 표시됩니다.
ResearcherID (WoS) Web of Science의 고유 연구자 식별번호입니다. 동명이인을 구분하고 연구자의 업적을 정확하게 추적할 수 있습니다.
AuthorsID (SCOPUS) SCOPUS의 고유 저자 식별번호입니다. 연구자의 모든 출판물을 추적하고 관리하는 데 사용됩니다.
Journal 논문이 게재된 학술지의 정식 명칭입니다.
JCR Abbreviation Journal Citation Reports에서 사용하는 저널의 공식 약어입니다. 저널을 간략하게 표기할 때 사용됩니다.
ISSN International Standard Serial Number. 국제표준연속간행물번호로, 인쇄본 저널에 부여되는 고유 식별번호입니다.
eISSN Electronic ISSN. 전자 버전 저널에 부여되는 고유 식별번호입니다.
Volume 저널의 권(Volume) 번호입니다. 보통 연도별로 하나의 권이 부여됩니다.
Issue 저널의 호(Issue) 번호입니다. 한 권 내에서 여러 호로 나누어 출판되는 경우가 많습니다.
WoS Edition Web of Science의 에디션입니다. SCIE(Science Citation Index Expanded), SSCI(Social Sciences Citation Index), AHCI(Arts & Humanities Citation Index) 등으로 구분됩니다.
WoS Category Web of Science의 주제 분류 카테고리입니다. 저널과 논문이 속한 학문 분야를 나타냅니다.
JCR Year 해당 저널의 JCR(Journal Citation Reports) 지표가 산출된 연도입니다.
IF (Impact Factor) 저널 영향력 지수. 최근 2년간 발표된 논문이 해당 연도에 평균적으로 인용된 횟수를 나타냅니다. 저널의 학술적 영향력을 나타내는 대표적인 지표입니다.
JCR (%) 해당 카테고리에서 저널이 위치하는 상위 백분율입니다. 값이 낮을수록 우수한 저널임을 의미합니다 (예: 5%는 상위 5%를 의미).
FWCI Field-Weighted Citation Impact. 분야별 가중 인용 영향력 지수입니다. 논문이 받은 인용을 동일 분야, 동일 연도, 동일 문헌 유형의 평균과 비교한 값입니다. 1.0이 평균이며, 1.0보다 높으면 평균 이상의 인용을 받았음을 의미합니다.
FWCI UpdateDate FWCI 값이 마지막으로 업데이트된 날짜입니다. FWCI는 인용이 누적됨에 따라 주기적으로 업데이트됩니다.
WOS Citation Web of Science에서 집계된 해당 논문의 총 인용 횟수입니다.
SCOPUS Citation SCOPUS에서 집계된 해당 논문의 총 인용 횟수입니다.
Keywords (WoS) 저자가 논문에서 직접 지정한 키워드입니다. Web of Science에 등록된 저자 키워드 목록입니다.
KeywordsPlus (WoS) Web of Science에서 자동으로 추출한 추가 키워드입니다. 논문의 참고문헌 제목에서 자주 등장하는 단어들로 생성됩니다.
Keywords (SCOPUS) 저자가 논문에서 직접 지정한 키워드입니다. SCOPUS에 등록된 저자 키워드 목록입니다.
KeywordsPlus (SCOPUS) SCOPUS에서 자동으로 추출하거나 추가한 색인 키워드입니다.
Language 논문이 작성된 언어입니다. 대부분 English이며, 그 외 다양한 언어로 작성된 논문이 포함될 수 있습니다.
Publication Year 논문이 출판된 연도입니다.
Publication Date 논문의 정확한 출판 날짜입니다 (년-월-일 형식).
DOI Digital Object Identifier. 디지털 객체 식별자로, 논문을 고유하게 식별하는 영구적인 식별번호입니다. 이를 통해 논문의 온라인 위치를 찾을 수 있습니다.